Literature DB >> 20118585

Enhancement of wettability and dissolution properties of cilostazol using the supercritical antisolvent process: effect of various additives.

Min-Soo Kim1, Jeong-Soo Kim, Sung-Joo Hwang.   

Abstract

The aim of this study was to improve wettability and dissolution rate of a poorly water-soluble drug, cilostazol, using the supercritical antisolvent (SAS) process. The solid state of particles precipitated from dichloromethane containing additives, including poloxamer 188, poloxamer 407, TPGS 1000, Gelucire 44/14 and Gelucire 50/13, in supercritical CO(2) medium were characterized by differential scanning calorimetry (DSC), powder X-ray diffraction (PXRD), FT-IR, particle size analysis, contact angle, and dissolution. Interestingly, the morphology of SAS particles processed with TPGS 1000, Gelucire 44/14 and Gelucire 50/13 changed to plate- or leaflet-shaped. Furthermore, the particle sizes of cilostazol processed with Gelucire 44/14 and Gelucire 50/13 were increased compared to cilostazol processed without additives. Poloxamer 188 and poloxamer 407 were superior in increasing the dissolution rate due to decreased particle size, the resulting increased surface area, and improved wettability. Micronization with the supercritical antisolvent process resulted in a significant decrease in mean particle size, and wettability of cilostazol was increased by using small amounts of hydrophilic additives.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20118585     DOI: 10.1248/cpb.58.230

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  6 in total

1.  Enhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process.

Authors:  Min-Soo Kim; Jeong-Soo Kim; Hee Jun Park; Won Kyung Cho; Kwang-Ho Cha; Sung-Joo Hwang
Journal:  Int J Nanomedicine       Date:  2011-11-24

2.  The influence of formulation and manufacturing process parameters on the characteristics of lyophilized orally disintegrating tablets.

Authors:  Rhys J Jones; Ali Rajabi-Siahboomi; Marina Levina; Yvonne Perrie; Afzal R Mohammed
Journal:  Pharmaceutics       Date:  2011-07-20       Impact factor: 6.321

3.  A Systematic Approach to the Development of Cilostazol Nanosuspension by Liquid Antisolvent Precipitation (LASP) and Its Combination with Ultrasound.

Authors:  Emilia Jakubowska; Bartłomiej Milanowski; Janina Lulek
Journal:  Int J Mol Sci       Date:  2021-11-17       Impact factor: 5.923

4.  Influence of hydrophilic additives on the supersaturation and bioavailability of dutasteride-loaded hydroxypropyl-β-cyclodextrin nanostructures.

Authors:  Min-Soo Kim
Journal:  Int J Nanomedicine       Date:  2013-05-20

5.  Improving dissolution and oral bioavailability of pranlukast hemihydrate by particle surface modification with surfactants and homogenization.

Authors:  Eun-Sol Ha; In-hwan Baek; Jin-Wook Yoo; Yunjin Jung; Min-Soo Kim
Journal:  Drug Des Devel Ther       Date:  2015-06-24       Impact factor: 4.162

6.  Formulation of cilostazol spherical agglomerates by crystallo-co-agglomeration technique and optimization using design of experimentation.

Authors:  Sanjeevani Shekhar Deshkar; Govind R Borde; Rupali N Kale; Balasaheb A Waghmare; Asha Biju Thomas
Journal:  Int J Pharm Investig       Date:  2017 Oct-Dec
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.